Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties

Abstract: Triterpenoids have been used for medicinal purposes in many Asian countries because of their anti-inflammatory, antioxidant, antiproliferative, anticancer, and anticarcinogenic properties. Bardoxolone methyl, the C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) known as CDDO-Me or RTA 402, is one of the derivatives of synthetic triterpenoids. CDDO-Me has been used for the treatment of chronic kidney disease, cancer (including leukemia and solid tumors), and other diseases. In this review, we will update our knowledge of the clinical pharmacokinetics and pharmacodynamics of CDDO-Me, highlighting its clinical benefits and the underlying mechanisms involved. The role of the Kelch-like erythroid cell-derived protein with CNC homology-associated protein 1 (Keap1)/the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway in the therapeutic activities of CDDO-Me will be discussed. CDDO-Me contains α,β-unsaturated carbonyl groups on rings A and C that can generate reversible adducts with the thiol groups of Cys residues in target proteins such as Keap1 and IκB kinase. At low nanomolar concentrations, CDDO-Me protects the cells against oxidative stress via inhibition of reactive oxygen species generation, while CDDO-Me at low micromolar concentrations induces apoptosis by increasing reactive oxygen species and decreasing intracellular glutathione levels. Through Keap1/Nrf2 and nuclear factor-κB pathways, this agent can modulate the activities of a number of important proteins that regulate inflammation, redox balance, cell proliferation and programmed cell death. In a Phase I trial in cancer patients, CDDO-Me was found to have a slow and saturable oral absorption, a relatively long terminal phase half-life (39 hours at 900 mg/day), nonlinearity (dose-dependent) at high doses (600–1,300 mg/day), and high interpatient variability. As a multifunctional agent, CDDO-Me has improved the renal function in patients with chronic kidney disease associated with type 2 diabetes. CDDO-Me has shown a promising anticancer effect in a Phase I trial. This agent is generally well tolerated, but it may increase adverse cardiovascular events. Presently, it is being further tested for the treatment of patients with chronic kidney disease, cancer, and pulmonary arterial hypertension.

Keywords: CDDO-Me, chronic kidney disease, cancer, pulmonary arterial hypertension, Nrf2, Keap1, NF-κB

Introduction

Triterpenoids are a large family of compounds synthesized in some plants, such as the chrysanthemum flower through the cyclization of squalene, that have been used in traditional Asian medicine for disease management.1,2 Naturally occurring triterpenoids like oleanolic acid (OA) and ursolic acid have only weak anti-inflammatory and anticarcinogenic activities. To increase their usefulness, a series of novel derivatives of OA have been synthesized.3 The synthetic triterpenoids, such as 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) and its derivatives, such as CDDO methyl ester...
(CDDO-Me), the methyl amide of CDDO (CDDO-Ma), the ethyl amide of CDDO (CDDO-Ea), and CDDO-imidazolide (CDDO-Im), are compounds originally developed for the prevention and treatment of inflammation and cancer. Their chemical structures are shown in Figure 1. These synthetic triterpenoids are potent inhibitors of the de novo synthesis of inflammatory enzymes such as inducible nitric oxide synthase and inducible cyclooxygenase 2. Bardoxolone methyl, also known as CDDO-Me or RTA 402, is more potent than CDDO in anticancer and cancer-preventive activities and in the activation of Kelch-like erythroid cell-derived protein with CNC homology-associated protein 1/nuclear factor erythroid 2-related factor 2/antioxidant response element (Keap1/Nrf2/ARE) pathway, which is involved in cytoprotection in the presence of excessive electrophiles or oxidative stress.

![Figure 1](image-url) Chemical structures of oleanolic acid, CDDO, CDDO-Me, CDDO-Ma, CDDO-Ea, and CDDO-Im.

**Abbreviations:** CDDO, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid; CDDO-Me, CDDO methyl ester; CDDO-Ma, CDDO methyl amide; CDDO-Ea, CDDO ethyl amide; CDDO-Im, CDDO imidazolide.
As a noncytotoxic and multifunctional drug, CDDO-Me has applications for the prevention and treatment of not only cancer, but also of many other diseases with an inflammatory component. The therapeutic effects of CDDO-Me have been tested in Phase III clinical trials for chronic kidney disease (CKD) and Phase I/II clinical trials for malignant diseases. In this review, we will update our knowledge of the pharmacokinetics, therapeutic effects, and mechanisms of action of CDDO-Me when used for the treatment of CKD, cancer, and other diseases. Both the clinical evidence and underlying mechanisms will be highlighted.

**CDDO-Me behaves as a potent Nrf2 activator and nuclear factor-κB (NF-κB) inhibitor**

Chemical modifications of OA on its three sites, the C-3 hydroxyl group, the C-12–C-13 double bond, and the C-28 carboxylic acid, have given rise to a series of new synthetic oleanane triterpenoids in order to increase their bioactivities. CDDO, CDDO-Me, and CDDO-Im possess better anti-inflammatory and cytoprotective activities than OA.

The molecular mechanism of action of the triterpenoids is believed to be mediated by the Michael addition with active nucleophilic groups on proteins, such as the thiol groups on cysteine residues. In the development of OA derivatives, two electrophilic Michael acceptor sites were incorporated in the A and C rings of OA. Structure-activity analyses have shown that α,β-unsaturated carbonyl groups at key positions on rings A and C are essential for maintaining the potent anti-inflammatory activity of synthetic triterpenoids. In cells, synthetic oleanane triterpenoids mediate their potent pharmacological effects in part through interactions with cellular nucleophiles such as discrete, redox-sensitive sulfhydryl groups of cysteine residues on proteins via reversible Michael addition. Therefore, one may expect that synthetic oleanane triterpenoids should have many cellular protein binding partners, depending on the cellular context and the nucleophilicity of specific cysteine residues in individual targets.

Initial screening studies for determining specific targets for CDDO and related derivatives have shown that both CDDO and CDDO-Me bind to peroxisome-activated receptor γ and exhibit partial agonist and antagonist activities. However, many of the actions of synthetic oleanane triterpenoids occur independently of this notoriously promiscuous nuclear receptor. Other direct molecular targets of CDDO-Me include Keap1 and IκB kinase (IKKβ). The structure of CDDO-Me is similar to 15-deoxy-Δ12,14-prostaglandin J₂ and related cyclopentenone prostaglandins, which are the endogenous activators of Nrf2 that play an important role in the resolution of inflammation and suppresses the activity of NF-κB (Figure 2). Binding of CDDO-Me to Keap1 disrupts its critical cysteine residues, leading to the release of Nrf2, which hinders its ubiquitination and finally leads to stabilization and nuclear translocation of NF-κB. In the nucleus, Nrf2 activates the transcription of phase 2 response genes, leading to a coordinated antioxidant and anti-inflammatory response. CDDO-Me also can bind to Cys-179 in the IκB activation loop and inhibit NF-κB activation. Binding of CDDO-Me to IKKβ prevents the release of NF-κB from its bound complex with IκB in the cytosol, thereby inhibiting NF-κB activation and downstream proinflammatory signaling pathways. It is important to recognize that binding of CDDO-Me to cysteine residues in specific proteins is both context-dependent and dose-dependent, which will be discussed later in this review. The nucleophilicity of the free sulfhydryl (-SH) groups in cysteine in a protein is markedly influenced by neighboring amino acids. Moreover, the unique stereochemistry of the oleanane scaffold prevents CDDO-Me from randomly alkylating protein targets.

A recent proteomic study in wild-type and Nrf2−/− mice has also provided evidence that CDDO-Me selectively activates the Keap1/Nrf2 pathway. Treatment of the wild-type mice with CDDO-Me at 3 mg/kg by intraperitoneal (ip) injection resulted in significantly altered expression of 43 proteins. Six proteins were regulated at both basal and inducible levels: cytochrome P450 2A5 (17.2-fold), glutathione S-transferase-Mu 3 (6.4-fold), glutathione S-transferase Mu 1 (5.9-fold), ectonucleoside-triphosphate diphosphohydrolase (4.6-fold), UDP-glucose-6-dehydrogenase (4.1-fold), and epoxide hydrolase (3.0-fold). Most of these proteins are regulated by Nrf2. However, only two proteins altered by CDDO-Me in wild-type mice were similarly affected in Nrf2−/− mice, demonstrating the high degree of selectivity of CDDO-Me for the Keap1/Nrf2 signaling pathway.

**Pharmacokinetics of CDDO-Me**

Due to the relatively low oral bioavailability of CDDO, new triterpenoids such as CDDO-Me with a higher oral bioavailability were synthesized. However, the oral bioavailability of unsolvated crystalline CDDO-Me was still relatively low. To improve this property, amorphous spray dried dispersions (SDD) CDDO-Me formulation has been used in the Phase III BEACON study evaluating the therapeutic effect of CDDO-Me in CKD. In a separate study, 30 mg of amorphous
SDD CDDO-Me formulation showed higher bioavailability than 150 mg of the crystalline formation, while achieving a similar overall exposure profile in healthy volunteers.10

Hong et al18 developed a fast liquid chromatography/mass spectrometric method to determine the pharmacokinetics of CDDO-Me in 47 patients with advanced, refractory solid tumors and lymphoid malignancies in a Phase I trials. The most common cancer types were melanoma (16 patients), colorectal (eight patients), renal cell (five patients), anaplastic thyroid (four patients), and non-Hodgkin’s lymphoma (three patients). The main purposes of this trial were to determine the dose-limiting toxicities, maximum tolerated dose, and appropriate dose for Phase II studies; to evaluate the single-dose and steady-state pharmacokinetic parameters; and to examine the antitumor activity. SDD CDDO-Me was administered orally once daily for 21 days of a 28-day cycle. The starting dose was 5 mg, which was one-tenth the dose causing severe toxicity in rats. Blood samples were collected before dosing and at 0.25, 0.50, 1.0, 2.0, 4.0, 6.0, 8.0, and 24 hours after taking both the first and last doses during cycle 1. The pharmacokinetic behavior of the tested formulation of CDDO-Me was characterized by a slow and saturable oral absorption, a relatively long terminal phase half-life (39±20 hours at 900 mg dose level, n=19), nonlinearity (dose-dependent) at high doses (600–1,300 mg/day), and high interpatient variability.18 The median time to maximum plasma concentration was 4.1±3.4 hours at 900 mg dose level (n=19). Mean steady-state minimum and maximum concentrations of CDDO-Me in plasma from patients with daily administration of 900 mg were 8.8±4.3 ng/mL and 24.7±13.3 ng/mL, with a peak-to-trough ratio of 2.8±1.6, indicating that the once daily dosing regimen effectively maintains plasma levels of the drug within a relatively narrow range in individual patients. There was a remarkable interpatient variability in the pharmacokinetic parameters of CDDO-Me, ranging from 64% to 77% for the first dose and 39% to 54% for the last dose among patients treated at 900 mg/day. The apparent oral clearance of CDDO-Me

Figure 2 CDDO-Me activates Nrf2 and upregulates the antioxidant response while suppressing NF-κB and diminishing proinflammatory signaling.

Abbreviations: CDDO-Me, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid methyl ester; Nrf2, nuclear factor erythroid 2-related factor 2; Keap1, Kelch-like erythroid cell-derived protein with CNC homology-associated protein 1; DNA, deoxyribonucleic acid; sMAF, small Maf protein; ARE, antioxidant response element; HO-1, heme oxygenase-1; NQO1, NAD(P)H quinone oxidoreductase 1; γ-GCL, γ-glutamylcysteine ligase; iKKβ, IκB kinase; IκBα, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; COX-2, cyclooxygenase 2; iNOS, inducible nitric oxide synthase; Bcl-xl, B-cell lymphoma extra-large; cIAPs, cellular inhibitors of apoptosis protein.

2078

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 54.70.40.11 on 05-Dec-2018
For personal use only.
Powered by TCPDF (www.tcpdf.org)
was significantly correlated with the daily dose, whereas the terminal phase half-life was independent of the dose, suggestive of an inverse relationship between the extent of absorption and dose. A relatively long terminal phase half-life of CDDO-Me indicated that once daily dosing regimen is appropriate for future Phase II studies.

CDDO-Me for the treatment of kidney diseases

Acute kidney disease

CDDO-Me and related analogues have demonstrated therapeutic efficacy in models of acute kidney injury (AKI).\(^3\) Wu et al\(^3\) pretreated mice with CDDO-Me twice a day for 2 days and then subjected the mice to an ischemic model of AKI. Marked protection was noted, as manifested by an almost complete prevention of postischemic azotemia and a corresponding reduction in renal histologic injuries. CDDO-Me exerted its beneficial effect by increasing the expression of genes previously shown to protect against ischemic AKI, including Nrf2, peroxisome-activated receptor \(\gamma\), and heme oxygenase-1 (HO-1). However, CDDO-Me’s effects on tubular and leukocyte HO-1 during ischemic AKI may be independent on Nrf2 pathway. It was found that CDDO-Me also ameliorated cisplatin-induced nephrotoxicity in this same study. In a recent study, CDDO-Me suppressed aristolochic acid (AA)-induced AKI via Keap1/Nrf2 pathway in male C57BL/6 mice.\(^3\) CDDO-Me at 10 mg/kg/day by ip was administered for 7 consecutive days, starting 2 days prior to aristolochic acid I (AAI) administration. CDDO-Me significantly upregulated renal Nrf2, NAD(P)H quinone oxidoreductase 1 (NQO1), and HO-1 expression and downregulated Keap1 expression compared with the AAI-treated group. Nrf2 was expressed both in the cytoplasm and nucleus of glomeruli and tubules, whereas NQO1 and HO-1 were localized in the cytoplasm of tubules only. These studies clearly demonstrate the renal protective effect of CDDO-Me via Nrf2 activation.

Chronic kidney disease

Given the role of impaired Nrf2 activity in CKD-associated oxidative stress and inflammation,\(^2\) CDDO-Me unexpectedly improved the renal function in patients with cancer during Phase I trials.\(^1\) Studies were designed to evaluate the effects of CDDO-Me in CKD patients with type 2 diabetes. In the first trial, 20 patients with moderate to severe CKD and type 2 diabetes were enrolled. Patients received 25 mg of CDDO-Me daily for 28 days, followed by 75 mg daily for another 28 days. Notably, there was a significant increase in estimated glomerular filtration rate (eGFR) at week 4 (+2.8 mL/min/1.73 m\(^2\)) at a dose of 25 mg/day and at week 8 (+7.2 mL/min/1.73 m\(^2\)) at a dose of 75 mg/day. The eGFR change paralleled a significant reduction in serum creatinine (–0.3 mg/dL) and blood urea nitrogen (BUN) (–4.9 mg/dL), along with an increase in creatinine clearance (+14.6 mL/min/1.73 m\(^2\)), without a change in the 24-hour creatinine excretion rate. Markers of vascular injury and inflammation presented improvement by treatment with CDDO-Me. No life-threatening adverse events or drug-related serious adverse events were reported.\(^3\)

The beneficial effect of CDDO-Me on eGFR was confirmed in a larger, multicenter, double-blind, randomized trial.\(^3\) Treatment with CDDO-Me at a target dose of 25, 75, or 150 mg once daily for 52 weeks led to sustained, significant improvements in the eGFR in patients receiving standard medical care for CKD and type 2 diabetes. A significant improvement in the primary endpoint (change of eGFR after 24 weeks postdosing) was observed in CDDO-Me-treated groups (+8.2, +11.4, and +10.4 mL/min/1.73 m\(^2\), respectively) versus 0 mL/min/1.73 m\(^2\) in the placebo group. The secondary endpoint (change of eGFR after 52 weeks postdosing) also was significantly improved in CDDO-Me-treated groups (+5.8, +10.5, and +9.3 mL/min/1.73 m\(^2\), respectively, versus 0). More patients in the placebo-treated group had an eGFR decrease more than 25% with respect to baseline value at 24 and 52 weeks postdosing. Additionally, serum BUN, phosphorus, and uric acid were significantly lower at 24 and 52 weeks postdosing in all CDDO-Me-treated groups when compared with the placebo-treated group. These results suggest that treatment with CDDO-Me may help retard disease progression in patients with advanced CKD and type 2 diabetes and justify further studies of CDDO-Me and related compounds.\(^3\) However, a higher rate of cardiovascular events with CDDO-Me than with placebo prompted termination of a Phase III trial.\(^1\) The potential reasons for the termination will be discussed later in this review.

The effect of eGFR increase and the termination of Phase III trial as mentioned previously triggered some studies to explore the mechanisms of CDDO-Me on renal protection. One of the potential mechanisms is that CDDO-Me can induce an antioxidant and anti-inflammatory response in various cells of renal origin. CDDO-Me can upregulate the expression of Nrf2 target genes such as HO-1, NQO1, and thioredoxin in mesangial cells (MCs). When these cells were exposed to albumin or tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)), CDDO-Me inhibited NF-kB activation and expression of cyclooxygenase 2, monocyte chemotactic protein-1, and
interleukin-1β (IL-1β), providing evidence that this drug attenuates inflammation induced by factors known to be upregulated in CKD. In proximal tubular epithelial cells, glomerular endothelial cells, and podocytes, CDDO-Me was also shown to induce Nrf2 targets, as well as attenuate NF-κB activation and its downstream signaling transduction. Therefore, the main mechanism of renal preventive action of CDDO-Me was believed to be the anti-inflammatory feature that was attributed to the activation of Nrf2, inhibition of NF-κB, and decreased oxidative stress.

Albuminuria induction effect of CDDO-Me was observed in the clinical trial. Reisman et al investigated whether the CDDO-Me-induced albuminuria resulted from the downregulation of megalin, a protein involved in the tubular reabsorption of albumin and lipid-bound proteins. Administration of CDDO-Me to cynomolgus monkeys significantly decreased the protein expression of megalin in renal tubules, which was inversely correlated with the urine albumin-to-creatinine ratio. Moreover, daily oral administration of CDDO-Me to monkeys for 1 year did not lead to any adverse effects on renal tissues but reduced serum creatinine and BUN, as observed in patients with CKD. The CDDO-Me-induced decrease in megalin corresponded with pharmacological induction of renal Nrf2 target genes. These findings suggest that the increase in albuminuria that accompanies CDDO-Me administration may result, at least in part, from reduced expression of megalin. This seems to occur without any adverse effects and with strong induction of Nrf2 target genes.

Since the contractile activity of MCs may influence glomerular filtration rate (GFR), Ding et al evaluated the effect of the synthetic triterpenoid CDDO-Me analog, RTA 405, on GFR in rats and on MC contractility in freshly isolated glomeruli. In rats, RTA 405 increased basal GFR, assessed by inulin clearance, and attenuated the angiotensin II-induced decline in GFR. RTA 405 increased the filtration fraction, but did not affect arterial blood pressure or renal plasma flow. Glomeruli from RTA 405-treated rats were resistant to angiotensin II-induced volume reduction ex vivo. In cultured MCs, angiotensin II-stimulated contraction was attenuated by RTA 405 in a dose- and time-dependent fashion. Further, Nrf2-targeted gene transcriptions in MCs were associated with decreased basal and reduced angiotensin II-stimulated hydrogen peroxide and calcium ion levels. These results implicate induction of Nrf2, reduction of intracellular reactive oxygen species levels, suppression of the glomerular MC Ca²⁺ response, and suppression of MC contraction as the underlying mechanisms contributing to the renal protective effect. Inhibition of MC contraction may lead to a relative increase in glomerular capillary surface area, resulting in improved GFR.

As noted previously, a higher rate of cardiovascular events with CDDO-Me than with placebo prompted termination of the Phase III trial in CKD therapy. It has been noted that the failure to the right clinical indication and heightened specificity of CDDO-Me led to termination of the phase III trial. Others demonstrated that the chemical structure of CDDO-Me was similar to that of cyclopentenone prostaglandins shown to cause renal vasodilatation. It is conceivable that CDDO-Me may have increased the eGFR by causing afferent arteriolar dilatation and increasing intraglomerular pressure. This hemodynamic effect may result in short-term hyperfiltration, which predisposes cells to accelerated renal function loss and progression of nephropathy in the long term.

**CDDO-Me for the treatment of cancer**

**Data from the preclinical studies**

In addition to its efficacy in chemical carcinogenesis models, CDDO-Me also significantly delays tumor development in various transgenic mouse models of prostate, breast, and pancreatic cancer. CDDO-Me was shown to modulate protein kinase B, NF-κB, telomerase reverse transcriptase, transcription factor signal transducers and activators of transcription 3 (STAT3), cyclin D1, human epidermal growth factor receptor 2 (EGFR2), Nrf2, and IKK signaling presenting an anticarcinogenic effect. The detailed mechanisms of this effect for CDDO-Me have been discussed in our another review recently published in *Molecular Cancer*.

CDDO-Me inhibited proliferation and induced apoptosis in vitro in a wide variety of human cancer cells. It has also been shown to inhibit the growth of tumors in the mouse models. Although the mechanisms of the anticancer effects of CDDO-Me are not fully understood, indications from both in vitro and in vivo studies suggest that CDDO-Me can indeed modulate multiple molecular targets that play a fundamental role in both development and progression of cancer. NF-κB, phosphoinositide 3-kinase/protein kinase B1/mammalian target of rapamycin, janus-activated kinase/STAT, and death receptor-induced extrinsic apoptotic pathways are the CDDO-Me’s main targets where it performs an anticancer effect. Telomere or telomerase and immune cells of different kinds of cancers are also the targets that are modulated by CDDO-Me.

Unlike kidney diseases described previously, there is little evidence that Nrf2 activation is required for much of
the anticancer activity of CDDO-Me. The most possible reason is that CDDO-Me targets the cysteine residues of multiple proteins in a dose-dependent manner. As mentioned previously, drugs that undergo Michael addition have different binding affinities for different target proteins. Low concentrations of drug might preferentially interact with targets such as Keap1 to release Nrf2 and activate the phase 2 cytoprotective pathway, whereas higher concentrations of triterpenoids might interact with target proteins with lower binding affinities such as tubulin or IKK to inhibit proliferation and induce apoptosis. Another reason for a low Nrf2 dependence by CDDO-Me is that cancer cells can hijack the Keap1/Nrf2/ARE system, acquiring malignant properties. Several mechanisms have been reported for the hijack effect of Keap1/Nrf2/ARE pathway: somatic mutations in Keap1 or Nrf2, deoxyribonucleic acid (DNA) hypermethylation at the promoter region of Keap1, the aberrant accumulation of proteins that disrupt the Keap1/Nrf2 interaction, transcriptional upregulation of the Nrf2 gene through oncogene-dependent signaling, and the modification of Keap1 protein through oncometabolites. The hijack effect can make CDDO-Me lose its Nrf2 activation function. Lastly, benign cells are under much greater control from inflammatory cells and other stromal cells in their microenvironment and, moreover, they have not yet reached a level of DNA damage that makes them autonomous. Therefore, enhancement of Nrf2 activity appears more obvious in benign states than in the malignant states.

Data from the clinical trials
CDDO-Me shows promise in preventive and therapeutic activities against several types of cancer not only in both in vitro and animal studies, but also in clinical trials. Nagaraj et al analyzed samples from 19 patients with pancreatic adenocarcinoma that were treated with CDDO-Me in the Phase I clinical trial RTA 402-C-0702. Patients were treated intravenously with gemcitabine (1,000 mg/m²) weekly on days 1, 8, and 15. CDDO-Me was administered orally once daily for 21 days. Nine patients received a dose of 150 mg/day; two patients, 200 mg/day; six patients, 250 mg/day; and two patients, 300 mg/day. CDDO-Me abrogated the immune suppressive effect of myeloid-derived suppressor cells (MDSCs) and improved immune responses in cancer patients. No toxicity attributed to CDDO-Me was observed.

Hong et al reported the data of Phase I clinical trial of CDDO-Me in 47 patients with advanced solid tumors and lymphoma. They found that CDDO-Me-induced dose limited toxicity was reversible and exhibited grade 3 liver transamini- nase elevation. The maximum tolerated dose was established as 900 mg/day. A complete tumor response occurred in a mantle cell lymphoma patient, and a partial response was observed in an anaplastic thyroid carcinoma patient. NQO1 messenger ribonucleic acid (mRNA) levels increased in peripheral blood mononuclear cells, and NF-κB and cyclin D1 levels decreased in tumor biopsies. They concluded that CDDO-Me was well tolerated with a maximum tolerated dose of 900 mg/day. For the observed objective tumor responses, CDDO-Me was suggested for further development in solid cancer (Table 1).

Treatment of other diseases by CDDO-Me
Besides kidney disease and malignant diseases, activation of the Nrf2/ARE and inhibition of NF-κB pathway by CDDO-Me should protect against a number of other diseases driven by inflammation and oxidative stress (Table 2).

Neuroprotective effect
Tran et al found that at low nanomolar concentrations, treatment of rat primary mesencephalon neuron/glial cultures with CDDO-Me resulted in attenuated lipopolysaccharide (LPS)-, TNF- or fibrillar β-amyloid 1–42 peptide-induced increases in reactive microglia and inflammatory gene expression without an overall effect on cell viability. In addition, CDDO-Me blocked death in the dopaminergic neuron-like cell line MN9D induced by conditioned media addition, CDDO-Me blocked death in the dopaminergic neuron-like cell line MN9D induced by conditioned media as 900 mg/day. A complete tumor response occurred in a mantle cell lymphoma patient, and a partial response was observed in an anaplastic thyroid carcinoma patient. NQO1 messenger ribonucleic acid (mRNA) levels increased in peripheral blood mononuclear cells, and NF-κB and cyclin D1 levels decreased in tumor biopsies. They concluded that CDDO-Me was well tolerated with a maximum tolerated dose of 900 mg/day. For the observed objective tumor responses, CDDO-Me was suggested for further development in solid cancer (Table 1).

Radioprotective effect
The activation of the Nrf2/ARE pathway by CDDO-Me protects cells from a variety of chemical or physical insults. Kim et al reported that CDDO-Me protected colonic epithelial cells against radiation-induced damage, in part, by enhancing signaling of the DNA damage response. Pretreatment
### Table 1 Therapeutic efficacy and side effects of CDDO-Me in clinical trials

<table>
<thead>
<tr>
<th>Indication</th>
<th>Phase</th>
<th>Treatment method</th>
<th>Sample size</th>
<th>Efficacy</th>
<th>Side effects</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 3b–4 CKD and type 2 diabetes</td>
<td>ii</td>
<td>25 mg of CDDO-Me daily for 28 days, followed by 75 mg daily for another 28 days</td>
<td>20 patients</td>
<td>The study found an improvement in 90% of patients' eGFR, with average in estimated glomerular filtration rate of 7.2 mL/min/1.73 m².</td>
<td>No life-threatening adverse events or drug-related serious adverse events</td>
<td>Pergola et al&lt;sup&gt;37&lt;/sup&gt;</td>
</tr>
<tr>
<td>CKD</td>
<td>ib</td>
<td>Placebo or CDDO-Me at a target dose of 25, 75, or 150 mg once daily</td>
<td>227 patients</td>
<td>eGFR improvement of 8.2±1.5 mL in 25 mg group, 11.4±1.5 mL in the 75 mg group, and 10.4±1.5 mL in the 150 mg group and maintained through week 52</td>
<td>Muscle spasms, hypomagnesemia, increases in alanine aminotransferase and gastrointestinal effects</td>
<td>Pergola et al&lt;sup&gt;38&lt;/sup&gt;</td>
</tr>
<tr>
<td>Type 2 diabetes mellitus and stage 4 CKD</td>
<td>iii</td>
<td>Placebo or CDDO-Me at a daily dose of 20 mg</td>
<td>2,185 patients</td>
<td>In the CDDO-Me group, ESRD developed in 43 patients, and 27 patients died from cardiovascular causes; in the placebo group, ESRD developed in 51 patients, and 19 patients died from cardiovascular causes.</td>
<td>Heart failure</td>
<td>de Zeeuw et al&lt;sup&gt;16&lt;/sup&gt;</td>
</tr>
<tr>
<td>Stage II–IV pancreatic adenocarcinoma</td>
<td>i</td>
<td>Various concentrations of CDDO-Me combined with gemcitabine</td>
<td>19 patients</td>
<td>Neutralizes the activity of MDSC and improves antitumor immune responses</td>
<td>No toxicity was observed</td>
<td>Nagaraj et al&lt;sup&gt;17&lt;/sup&gt;</td>
</tr>
<tr>
<td>Solid tumors and lymphomas</td>
<td>i</td>
<td>Administered orally once daily for 21 consecutive days of a 28-day cycle for up to 12 cycles from 5 mg/day to 1,300 mg/day</td>
<td>47 patients</td>
<td>The MTD was established as 900 mg/day. A complete tumor response occurred in a mantle cell lymphoma patient</td>
<td>Fatigue, nausea, anorexia and liver transaminase elevations</td>
<td>Hong et al&lt;sup&gt;18&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

**Abbreviations:** CDDO-Me, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid methyl ester; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; MDSC, myeloid-derived suppressor cells; MTD, maximum tolerated dose.
## Table 2 Registered clinical trials for CDDO-Me

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Phase</th>
<th>Purpose(s)</th>
<th>Status</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy volunteers</td>
<td>I</td>
<td>Determine the effect of food on a single dose of 20 mg CDDO-Me administered to normal healthy adult subjects</td>
<td>Completed</td>
<td>NCT01461161</td>
</tr>
<tr>
<td>Healthy volunteers</td>
<td>I</td>
<td>This is a single-center, multiple-dose, randomized, double-blind, double-dummy, placebo-controlled, active-comparator, parallel study in healthy volunteers</td>
<td>Completed</td>
<td>NCT01689116</td>
</tr>
<tr>
<td>Healthy volunteers</td>
<td>I</td>
<td>Determine the absorption and excretion kinetics of CDDO-Me and to determine and characterize metabolites present in plasma, urine, and feces in men following a single oral dose or 20 mg of [14C]-CDDO-Me</td>
<td>Completed</td>
<td>NCT01503866</td>
</tr>
<tr>
<td>Healthy volunteers</td>
<td>I</td>
<td>Evaluate the potential effect of CDDO-Me on the pharmacokinetics of digoxin and rosuvastatin and to assess the safety of the concomitant administration of CDDO-Me with digoxin or rosuvastatin</td>
<td>Completed</td>
<td>NCT01598363</td>
</tr>
<tr>
<td>Hepatic impairment and healthy volunteers</td>
<td>I</td>
<td>Assess the pharmacokinetic profile of CDDO-Me following a single oral dose of 20 mg CDDO-Me in subjects with mild, moderate, and severe hepatic impairment, as compared with healthy volunteers</td>
<td>Completed</td>
<td>NCT01563562</td>
</tr>
<tr>
<td>Chronic renal insufficiency and type 2 diabetes</td>
<td>I</td>
<td>Evaluate the pharmacokinetics and pharmacodynamics of CDDO-Me in patients with CKD and type 2 diabetes</td>
<td>Terminated</td>
<td>NCT01549769</td>
</tr>
<tr>
<td>CKD and type 2 diabetes</td>
<td>I</td>
<td>This is a 24-week multicenter, double-blind, randomized, exploratory study of CDDO-Me treatment in 18 patients with Stage 3 CKD and diabetes to ensure at least 15 patients complete the study for evaluation of the primary endpoints</td>
<td>Terminated</td>
<td>NCT01500798</td>
</tr>
<tr>
<td>Lymphoid malignancies</td>
<td></td>
<td>Determine the DLT, MTD, and recommended Phase II dose of RTA 402 capsules in patients with advanced solid tumors or lymphoid malignancies</td>
<td>Completed</td>
<td>NCT00508807</td>
</tr>
<tr>
<td>Liver disease</td>
<td>I, II</td>
<td>Assesses the safety and tolerability of CDDO-Me in patients with liver disease</td>
<td>Terminated</td>
<td>NCT00550849</td>
</tr>
<tr>
<td>CKD and type 2 diabetes</td>
<td>II</td>
<td>Assesses the effects of CDDO-Me in patients with type 2 diabetes and CKD</td>
<td>Completed</td>
<td>NCT00811889</td>
</tr>
<tr>
<td>Diabetic nephropathy</td>
<td>II</td>
<td>Assesses the effects of a new formulation of CDDO-Me on eGFR in patients with CKD and type 2 diabetes</td>
<td>Completed</td>
<td>NCT01053936</td>
</tr>
<tr>
<td>Diabetic nephropathy</td>
<td>II</td>
<td>Determine the effects of three different doses of CDDO-Me administered orally on the kidney function in patients with diabetic nephropathy</td>
<td>Completed</td>
<td>NCT00664027</td>
</tr>
<tr>
<td>Pulmonary arterial hypertension</td>
<td>II</td>
<td>Assesses the safety and efficacy of CDDO-Me relative to placebo in patients with pulmonary arterial hypertension to determine the recommended dose range and evaluate the change from baseline in 6MWD following 16 weeks of study participation</td>
<td>Recruiting</td>
<td>NCT02036970</td>
</tr>
<tr>
<td>Chronic renal insufficiency and type 2 diabetes</td>
<td>III</td>
<td>Assesses the efficacy of CDDO-Me relative to placebo in delaying progression to ESRD and cardiovascular deaths in patients with Stage 4 CKD and type 2 diabetes receiving standard of care</td>
<td>Terminated</td>
<td>NCT01351675</td>
</tr>
</tbody>
</table>

**Note:** Data are from [www.clinicaltrials.gov](http://www.clinicaltrials.gov). **Abbreviations:** CDDO-Me, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid methyl ester; CKD, chronic kidney disease; DLT, dose limited toxicity; MTD, maximum tolerated dose; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; 6MWD, 6-minute walk distance.
with CDDO-Me reduced the frequency of both G1 and S/G2 chromosome aberrations and enhanced the disappearance of repairosomes (C-terminal binding protein interacting protein, Rad51, and p53 binding protein-1 foci) after irradiation. CDDO-Me protected cells from radiation toxicity in an Nrf2-dependent manner. The p53 binding protein-1 promoter contains three antioxidant responsive elements in which Nrf2 directly binds following CDDO-Me treatment. These results demonstrate that Nrf2 activation by synthetic triterpenoids is a promising candidate target to protect the gastrointestinal tract against acute irradiation. Eskiocak et al85 found that CDDO-Me was able to activate the Nrf2/ARE pathway and protect human colon epithelial cells against radiation-induced DNA transformation. Pretreatment of cells with CDDO-Me prevented the heavy-ion-induced increase in proliferation rate and anchorage-dependent and -independent colony formation efficiencies.

However, an Nrf2-independent radiation protective effect of CDDO-Me was also observed in some studies. Kim et al86 investigated whether CDDO-Me mitigated radiation-induced DNA damage in immortalized normal human colonic epithelial cells and bronchial epithelial cells. DNA damage and clonogenic survival were assessed after treatment with CDDO-Me postirradiation. They observed that treatment with CDDO-Me within 30 minutes after irradiation improved both DNA damage repair and clonogenic survival. CDDO-Me activates EGFR-related DNA repair responses. In the presence of CDDO-Me, EGFR is phosphorylated and translocates into the nucleus where it interacts with DNA-dependent protein kinase, catalytic subunit (DNA-PKcs). CDDO-Me-mediated mitigation activity can be abrogated through depletion of EGFR, ectopic overexpression of mutant EGFR, or inhibition of DNA-PKcs, which is independent of Nrf2.

Antifibrotic effect
The CDDO-Me also provides protection against radiation- or chemical-induced fibrosis of different organs. Kulkarni et al87 explored whether CDDO-Me could reduce lung inflammation, fibrosis, and lung function impairment in a bleomycin-induced lung injury and fibrosis model. They found that CDDO-Me had broad anti-inflammatory effects against multiple cytokines, such as transforming growth factor-β (TGF-β) and IL-6, which are involved in the initiation and development of fibrosis. They indicated that early administration of CDDO-Me potently inhibited inflammation, reduced fibrotic outcomes, and significantly improved lung function in bleomycin-treated mice.

Wounds to the cornea, the second most common cause of blindness, initiate the release of cytokines such as TGF-β that induce keratocytes to differentiate into myofibroblasts. Kuriyan et al88 reported that CDDO-Me could function as a potent antifibrotic agent for cultured human corneal fibroblasts stimulated to differentiate into myofibroblasts by TGF-β. CDDO-Me inhibited the differentiation of primary corneal fibroblasts treated with TGF-β into myofibroblasts, as measured by the complete suppression of the in vitro production of α-smooth muscle actin, collagen, and fibronectin. Reactivity with intracellular nucleophiles may be a potential mechanism through which CDDO-Me was able to inhibit myofibroblast differentiation.

Inflammatory/metabolic disorders
Auletta et al89 found that pretreatment with oral CDDO-Me significantly improved survival following lethal-dose LPS challenge in mice. CDDO-Me extends the survival of mice challenged with LPS and decreases circulating levels of IL-6, IL-12, IL-17, IL-23, and interferons without altering the numbers or subtypes of immune cells.

Saha et al90 reported that CDDO-Me ameliorated diabetes in mice fed a high-fat diet or in mice with a defective leptin receptor (Leprdb/db). Oral CDDO-Me administration reduced total body fat, plasma triglyceride, and free fatty acid levels. It also improved glucose and insulin tolerance tests. Although CDDO-Me reduces total body fat and suppresses production of the proinflammatory cytokines IL-1, IL-6, and TNF-α in mice fed a high-fat diet, the antidiabetic effects of this agent may be mediated by stimulating phosphorylation of liver kinase B1 and AMP-activated protein kinase (AMPK) in muscle and liver, as knockdown of AMPK reduces glucose uptake in cells treated with CDDO-Me.

Pulmonary arterial hypertension
Pulmonary arterial hypertension is a life-threatening disease involving endothelial dysfunction, vasoconstriction in small pulmonary arteries, aberrant proliferation of certain vascular cells, and dysregulated inflammatory signaling leading to vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy.91 Preclinical data have demonstrated that CDDO-Me could modulate the endothelin (ET) pathway and reduce vascular inflammation. Chin et al92 found CDDO-Me administration was associated with decreases in ET-1 secretion and ET receptors type A (ETA) receptor expression. Furthermore, the ET pathway has been identified as a target of NF-kB, with ETA expression decreased in renal artery organ cultures treated with
direct NF-κB inhibitors. Thus, the inhibitory effects of CDDO-Me on the NF-κB pathway may contribute to the reduced activity of ET pathway. In addition, CDDO-Me and related compounds have highly potent antioxidant, anti-inflammatory properties, as well as antiproliferative and antifibrotic effects, which has been discussed in the previous part of this review. On the basis of these data, CDDO-Me is currently being studied in patients with pulmonary arterial hypertension in a Phase I trial.

Graft-versus-host disease

Although the mechanisms responsible for treatment of graft-versus-host disease (GVHD) by the CDDO-Me are not completely understood, several clues have emerged. Ames et al. observed that CDDO-Me promoted myelopoesis in both naïve and transplanted mice. After sublethal total body irradiation, mice pretreated with CDDO-Me further displayed an accelerated recovery of myeloid progenitors and total nucleated cells in the spleen. A similar expansion of myeloid and myeloid progenitors was noted with CDDO-Me treatment after syngeneic bone marrow transplantation. Compared with granulocyte colony-stimulating factor, CDDO-Me not only expanded CD11b+ Gr-1+ myeloid cells in the bone marrow and spleen, but also increased the granulocyte macrophage-colony forming unit colonies in the spleen, bone marrow, and blood. Additionally, the number of granulocyte macrophage-colony forming units and hematopoietic progenitor cells in the spleen and bone marrow showed a significant increase in mice that received CDDO-Me. In vitro studies also showed that CDDO-Me was sufficient to stimulate colony growth of naïve bone marrow cells in suboptimal colony-stimulating cytokine conditions. These results suggest that CDDO-Me may be of use posttransplantation to accelerate myeloid recovery in addition to the prevention of GVHD. Li et al. found that CDDO-Me had an increased ability to inhibit allogeneic T cell responses and induce cell death of alloreactive T cells in vitro. Administration of CDDO-Me to mice following allogeneic bone marrow transplantation resulted in significant and increased protection from lethal acute GVHD compared with CDDO. This was associated with reduced donor T cell proliferation, decreased adhesion molecule (α4β7 integrin) expression on the donor T cells, and reduced production of the proinflammatory cytokine TNF-α. These results suggest that CDDO-Me may be of significant benefit in suppressing acute GVHD, while preserving or possibly even augmenting graft-versus-tumor effects if it is applied together with allogeneic bone marrow transplantation in cancer.

Conclusion and future perspective

Inflammation and oxidative stress are hallmarks and mediators of the progression of most diseases. Previous studies with CDDO-Me have demonstrated that this compound had the capability of modifying a wide variety of proteins through nucleophilic attack and Michael addition, particularly at vulnerable -SH groups. The specific structure supports CDDO-Me to upregulate the antioxidant response, while diminishing proinflammatory signaling. Moreover, because large collections of regulatory proteins have reactive -SH groups, the targets of CDDO-Me are multiple, and the interaction between CDDO-Me and targets may result in a broad collection of direct and indirect effects. As a multifunctional agent, the therapeutic effects of CDDO-Me have been tested in clinical trials for CKD and malignant diseases. The potential role of CDDO-Me in treatment of other diseases is being explored in both in vivo and in vitro models. In the future, the underlying mechanisms of therapeutic effects for CDDO-Me should be explored further to identify new indications for this multifunctional drug. In addition, the combined use of CDDO-Me with other agents or targeted therapy should be examined. The dose–response and dose–toxicity relationships for CDDOM-Me should be established to optimize its dosing regimens. The data on its disposition, metabolism, and transport are lacking. Finally, although the agent appears to be well tolerated and side effects appear to be largely mild, transient, and self-limiting, additional safety data are eagerly awaited.

Disclosure

The authors report no conflicts of interest in this work.


